JY
TENX icon

Jeff Yass’s Tenax Therapeutics TENX Stock Holding History

Jeff Yass’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Buy
+235,200
New +$3M ﹤0.01% 5362
2016
Q3 		– Sell
-1
Closed -$43K – 9041
2016
Q2 		$43K Buy
+1
New +$83.4K ﹤0.01% 8273
2014
Q3 		– Sell
-4
Closed -$543K – 9944
2014
Q2 		$543K Buy
+4
New +$617K ﹤0.01% 7307

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jeff Yass's TENX Position: Q2 2026 in Review

Jeff Yass increased its Tenax Therapeutics (TENX) stake by 898% in Q2 2026, buying an estimated $3.32M and bringing the position to 289,164 shares worth $4.21M. The position accounts for ﹤0.01% of the portfolio, ranked #4959.

Jeff Yass first reported a position in TENX in Q1 2014 and has held it in 7 quarters since. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Jeff Yass held 289,164 shares of Tenax Therapeutics worth $4.21M as of Q2 2026.
  • Jeff Yass bought 260,187 Tenax Therapeutics shares in Q2 2026, an estimated $3.32M.
  • Tenax Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4959 holding.
  • Jeff Yass first reported a position in Tenax Therapeutics in Q1 2014 and has held it in 7 quarters since.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.